Literature DB >> 33871806

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease.

Christopher M Rubino1, Nikolas J Onufrak2, Jakko van Ingen3, David E Griffith4,5, Sujata M Bhavnani2, Dayton W Yuen6, Kevin C Mange6, Kevin L Winthrop7.   

Abstract

Entities:  

Year:  2021        PMID： 33871806     DOI： 10.1007/s13318-021-00687-z

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


× No keyword cloud information.
  1 in total

Review 1.  Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.

Authors:  Sheridan M Hoy
Journal:  Clin Drug Investig       Date:  2021-03-16       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.